PubMed Health⌕ Search

PubMed · 17225110

A microscale device for measuring emissions from materials for indoor use.

Abstract

Emission test chambers or cells are used to determine organic vapour emissions from construction products under controlled conditions. Polymeric car trim component emissions are typically evaluated using direct thermal desorption/extraction. The Microchamber/Thermal Extractor (mu-CTE, Markes International) was developed to provide both a complementary tool for rapid screening of volatile organic compound (VOC) emissions--suitable for industrial quality control--and a means for thermal extraction of larger, more representative samples of car trim components. To determine the degree of correlation between conventional emission test methods and the microchamber, experiments were carried out under different conditions of temperature, air change rate and sample conditioning time. Good quantitative and qualitative correlation was obtained for measurements at ambient temperature. Moreover, it was shown that ambient-temperature emissions data collected using the mu-CTE as rapidly as possible--i.e. with minimal or no sample conditioning time--nevertheless provided a reliable guide as to how well that material would perform in subsequent 3-day chamber tests of VOC emissions. The parameters found to have the greatest influence on data correlation for experiments carried out at elevated temperatures were the sample mass (for bulk emissions testing) and the conditioning time. The results also showed that, within the constraints of inherent sample homogeneity, the mu-CTE gave reproducible emissions data, despite its small sample size/capacity relative to that of conventional chambers. Preliminary results of modelling the air flow within a microchamber using computational fluid dynamics showed a high degree of turbulent flow and two potential areas of still air which could cause sink effects. However, the experimental data reported here and in previous studies showed enhanced recovery of semivolatile components from the mu-CTE relative to a recovery from a 1 m(3) conventional chamber. This indicates that if these areas of relatively still air are present within the microchamber, they do not appear to be significant in practice.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Schripp, B Nachtwey, J Toelke, T Salthammer, E Uhde, M Wensing, M Bahadir. 2007-01-16. A microscale device for measuring emissions from materials for indoor use.. https://doi.org/10.1007/s00216-006-1057-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗